Showing posts with label MTHFR. Show all posts
Showing posts with label MTHFR. Show all posts

Friday, 16 March 2012

Susan Boyle plans for musical

Susan Boyle plans to star in a musical about her life.

The Scottish singing sensation, who shot to worldwide fame after appearing on UK TV talent show Britain's Got Talent in 2009, is in talks to have her meteoric rise to fame chronicled in a new stage production and even hopes to take the lead role in the show.

She said: "I'm definitely going to be on stage. I'd rather that than having to sit watching people up there looking like me.

"I want to be doing the music parts, so I'll be coming in and out of the show. I'm looking forward to doing some live work. It'll be really nice to see so many of the people who have supported me in person."

Producers are reportedly planning to take the show - which will chronicle the 49-year-old star's modest upbringing in Blackburn, West Lothian, her period living alone with her cat and her rise to stardom - on a huge UK tour late next year as they believe it will be extremely popular.

A source told The Sun newspaper: "Susan has incredibly loyal fans. People will be travelling from all over the world to see her perform in her own musical.

"I wouldn't be surprised if some of them book tickets to watch it five nights in a row."

Tuesday, 13 March 2012

U.K. to back Innovation Universities project

The United Kingdom is committed to supporting India as it develops 14 world-class Innovation Universities, said David Willetts, British Minister for Universities and Science.

Addressing academics at IIT-Madras Research Park, Mr. Willetts said eight U.K. universities – Oxford, Cambridge, Imperial, Essex, Birmingham, Newcastle, Exeter and the Open University – are eager to forge links during the design and eventual creation of the new Innovation Universities.

“We are keen to identify 14 British universities that can work alongside from the beginning. After talks with Kapil Sibal, I will go back to Britain to identify the 14 British universities to match up with the universities here,” the British Minister said.

Keen on flow of postgraduate and research students and academics between the two countries, Mr. Willetts said he would encourage the British academics to come to India. “There is scope for PG and Ph.D students to study in both countries to obtain a single award. Twinning arrangements between universities sharing staff and resources is beneficial,” he said, outlining the broad contour for collaboration.

The UK already has more than 80 university-related collaborations up and running in India, making it the most active international partner here.

To move things on substantially, Mr. Willetts said he would be visiting India again in November with leading UK university vice-chancellors to establish a framework for collaboration as India and the UK have a solid base to build on.

Recent commitments on co-funded research projects are worth about £60 million. Indeed, funding pledged by the UK bodies for collaboration with India this year has already approached 1 per cent of its science budget, a level that some argue should be the budget set aside for international collaboration, Mr. Willetts said. Jointly funded and administered research programmes will concentrate on priority areas for both countries – food security, water resources and sustainable energy. The UK has offered to commit up to £6 million for research in areas such as off-grid power generation technologies and ICT to improve services in, and the economic capacity of, rural communities in both countries. In the area of civil nuclear energy, the UK Engineering and Physical Sciences Research Council and India's Department of Atomic Energy are collaborating on five new projects, including areas such as plant safety and nuclear waste management, the British Minister said.

Mr. Willetts held discussions with IIT-M officials led by its Director M.S. Ananth, and then visited facilities at the TeNet Laboratory and Research Park on the campus.

Friday, 2 March 2012

Genetic Data Nix Folate Role in Heart Disease

The final nail may have been placed in the coffin of homocysteine-lowering therapy as a preventive measure for coronary heart disease.

The overall result from large, unpublished datasets shows lifelong moderate homocysteine elevation has little or no effect on coronary heart disease.

A comprehensive analysis -- including published and unpublished research that involved more than 236,000 participants -- suggests that even lifelong exposure to elevated homocysteine "has little or no effect," according to Robert Clarke, MD, of the Clinical Trial Service Unit at the University of Oxford, in Oxford, England, and colleagues.

The key finding is that, in several large unpublished datasets, genetic variation that increases or decreases natural homocysteine levels did not significantly affect the risk of coronary heart disease, Clarke and colleagues reported online in PLoS Medicine.

That was coupled with a null effect in an updated meta-analysis of 10 clinical trials testing the effect of folic acid, a homocysteine-lowering compound.

Taken together, that evidence suggests that a significant but modest benefit of lower homocysteine in an updated meta-analysis of 86 published case-control studies was an "artifact of publication bias," the researchers argued.

Clarke and colleagues noted that a common genetic variant -- named C677T -- in the methylene tetrahydrofolate reductase gene (MTHFR) markedly affects homocysteine levels.

Specifically, people with the TT genotype (individuals in whom both copies of the MTHFR gene have the nucleotide thymine at position 677) of the C677T polymorphism have natural levels that are about 20% higher than those with the CC variant. The CT variant has an effect that is intermediate but closer to CC than TT.

That suggests the possibility of a natural "Mendelian" experiment, and luckily the increasing use of large scale-genomics analysis has led to the creation of 19 large datasets -- with a total of more than 100,000 participants -- in which variation in the MTHFR gene was analyzed, although not as a primary focus.

Clarke and colleagues designated those studies as "unpublished" because odds ratios for coronary heart disease were not the primary aim and have not been reported. The studies had a total of 48,175 coronary heart disease cases and 67,961 controls.

If the associations seen in the earlier case-control studies were causal, the researchers argued, the 20% higher homocysteine in those with the TT variant should imply about an 8% increase in coronary heart disease risk, compared with CC carriers.

But a meta-analysis of the effect of the TT variant in the 19 studies showed a non-significant odds ratio of 1.02, with a 95% confidence interval from 0.98 to 1.07, they reported.

Even in the sub-population of participants who had not been given folate supplements in food, where the effect of the TT variant might be expected to be stronger, it remained non-significant, with an odds ratio of 1.01.

On the other hand, Clarke and colleagues reported, the updated analysis of the 86 biochemical studies -- with 28,617 cases and 41,857 controls -- suggested that having the TT variant increased the risk of coronary heart disease by 15% (odds ratio 1.15, 95% CI from 1.09 to 1.21).

The results of the two analyses are "discrepant," the researchers noted, and the discrepancy "is too extreme to be plausibly dismissed as a chance finding."

Instead, they argued for a "substantial" effect of publication bias.

To bolster the argument, they noted that their analysis of the 10 intervention studies, with a total of more than 50,000 participants, found that lowering homocysteine for at least five years had no significant effect on the risk of coronary heart disease. The odds ratio was 1.02 (95% CI from 0.96 to 1.08).

"Both the genetic studies and the trials argue against the use of (homocysteine-lowering agents) as a means of reducing coronary heart disease risk," they concluded.